Tandem Diabetes Care
TNDM
291 hedge funds and large institutions have $2.63B invested in Tandem Diabetes Care in 2024 Q1 according to their latest regulatory filings, with 54 funds opening new positions, 122 increasing their positions, 79 reducing their positions, and 29 closing their positions.
1,218% more call options, than puts
Call options by funds: $121M | Put options by funds: $9.18M
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
86% more first-time investments, than exits
New positions opened: 54 | Existing positions closed: 29
54% more repeat investments, than reductions
Existing positions increased: 122 | Existing positions reduced: 79
24% more capital invested
Capital invested by funds: $2.12B → $2.63B (+$503M)
9% more funds holding
Funds holding: 268 → 291 (+23)
2.94% more ownership
Funds ownership: 110.01% → 112.95% (+2.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$74.2M |
| 2 |
PWAM
Park West Asset Management
San Francisco,
California
|
+$37.4M |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$35.3M |
| 4 |
Jennison Associates
New York
|
+$33.9M |
| 5 |
FAM
Fred Alger Management
New York
|
+$32M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
Eminence Capital
New York
|
-$153M |
| 2 |
Capital World Investors
Los Angeles,
California
|
-$72.8M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$51.6M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$25.6M |
| 5 |
Voloridge Investment Management
Jupiter,
Florida
|
-$11.5M |
TNDM Hedge Fund Activity: Q1 2024 in Review
291 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Tandem Diabetes Care (TNDM) for Q1 2024, worth a combined $2.63B — up 24% from $2.12B a quarter earlier.
Buyers outnumbered sellers: 54 funds opened new TNDM positions and 29 closed out — a net gain of 25 holders — while 122 added to existing stakes and 79 trimmed.
The largest buyer was Marshall Wace, adding an estimated $74.2M. The largest seller was Eminence Capital, exiting entirely with an estimated $153M sold.
- 291 institutional investors held Tandem Diabetes Care (TNDM) as of Q1 2024, up from 268 in Q4 2023.
- Funds reported $2.63B of Tandem Diabetes Care stock for Q1 2024, up 24% quarter-over-quarter.
- 54 funds opened new Tandem Diabetes Care positions in Q1 2024 and 29 closed out, a net change of +25 holders.
- The largest Tandem Diabetes Care buyer in Q1 2024 was Marshall Wace, an estimated $74.2M added.
- The largest Tandem Diabetes Care seller in Q1 2024 was Eminence Capital, an estimated $153M sold.
Based on aggregated 13F filings for Q1 2024.